Carcinoma, Non-Small-Cell Lung Clinical Trials

A listing of 40 Carcinoma, Non-Small-Cell Lung clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Carcinoma, Non-Small-Cell Lung

13 - 24 of 40

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 40 active clinical trials seeking participants for Carcinoma, Non-Small-Cell Lung research studies. The states with the highest number of trials for Carcinoma, Non-Small-Cell Lung participants are California, Texas, Florida and New York.

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Featured Trial

Chronic Kidney Disease (CKD) Clinical Study

Recruiting

A clinical study for people that suffer with Chronic Kidney Disease (CKD)

Conditions:

Chronic Kidney Disease (CKD)

Learn More

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

NCT05983133

Recruiting

This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants.... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California +22 locations

Ronald Reagan UCLA Medical Center, Los Angeles, California

UCLA Hematology/Oncology, Los Angeles, California

Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California

UCLA Hematology/Oncology - Santa Monica, Santa Monica, California

Moffitt Cancer Center McKinley Hospital, Tampa, Florida

Moffitt Cancer Center, Tampa, Florida

University of Iowa, Iowa City, Iowa

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan

Hackensack University Medical Center, Hackensack, New Jersey

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Atrium Health Wake forest Baptist, Winston-Salem, North Carolina

Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Providence Cancer Institute Franz Clinic, Portland, Oregon

Providence Portland Medical Center, Portland, Oregon

MD Anderson Cancer Center - University of Texas, Houston, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah

Huntsman Cancer Institute, University Of Utah, Salt Lake City, Utah

University College London Hospital, NIHR UCLH Clinical Research Facility, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma

Learn More ›

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662

Recruiting

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Highlands Oncology Group, PA, Fayetteville, Arkansas +24 locations

Highlands Oncology Group, PA, Fayetteville, Arkansas

Highlands Oncology Group, PA, Rogers, Arkansas

Highlands Oncology Group, Springdale, Arkansas

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

City of Hope Investigational Drug Service (IDS), Duarte, California

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado

University of Colorado Hospital - Anschutz Outpatient Pavilion, Aurora, Colorado

University of Colorado Hospital- Anschutz Cancer Pavilion (ACP), Aurora, Colorado

University of Colorado Hospital, Aurora, Colorado

START Midwest, Grand Rapids, Michigan

Siteman Cancer Center - West County, Creve Coeur, Missouri

Siteman Cancer Center - North County, Florissant, Missouri

Siteman Cancer Center, Saint Louis, Missouri

Barnes-Jewish Hospital, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Siteman Cancer Center - South County, Saint Louis, Missouri

Siteman Cancer Center - St Peters, Saint Peters, Missouri

Duke University Medical Center, lnvestigational Chemotherapy Service, Durham, North Carolina

Duke University Medical Center, Durham, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

West Chester Hospital, West Chester, Ohio

Rhode Island Hospital, Providence, Rhode Island

Miriam Hospital, Providence, Rhode Island

University of Texas MD Anderson Cancer Center, Houston, Texas

Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076

Recruiting

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Southern Cancer Center, PC, Daphne, Alabama +122 locations

Southern Cancer Center, PC, Daphne, Alabama

Clearview Cancer Institute, Huntsville, Alabama

Cancer Treatment Center of America Phoenix, Goodyear, Arizona

City of Hope Corona, Corona, California

City of Hope, Duarte, California

Providence Medical Foundation, Fullerton, California

The Oncology Institute of Hope and Innovation, Glendale, California

Oncology Physicians Network Healthcare, Glendale, California

Los Angeles Cancer Network, Glendale, California

Glendale Adventist Medical Center, Glendale, California

Marin Cancer Center, Greenbrae, California

City of Hope Seacliff, Huntington Beach, California

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

University of California San Diego Health, La Jolla, California

City of Hope Antelope Valley, Lancaster, California

City of Hope Long Beach Elm, Long Beach, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

Cedars Sinai Medical Center, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Valkyrie Clinical Trials, Murrieta, California

Kaiser Permanente Oakland Medical Center, Oakland, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

University of California Irvine, Orange, California

Kaiser Permanente Roseville Medical Center, Roseville, California

Sutter Institute for Medical Research, Sacramento, California

Kaiser Permanente San Francisco Medical Center, San Francisco, California

UCSF Zuckerberg San Francisco General Hospital, San Francisco, California

Sansum Clinic, Santa Barbara, California

Kaiser Permanente Santa Clara Medical Center, Santa Clara, California

Providence Medical Foundation, Santa Rosa, California

City of Hope South Pasadena, South Pasadena, California

City of Hope Upland, Upland, California

Kaiser Permanente Northern California, Vallejo, California

Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, California

John Muir Health Clinical Research Center, Walnut Creek, California

Saint Josephs Hospital Cancer Centers of Colorado, Denver, Colorado

Lutheran Hospital Cancer Centers of Colorado, Golden, Colorado

Rocky Mountain Cancer Centers, Lone Tree, Colorado

Yale New Haven Hospital Yale Cancer Center, New Haven, Connecticut

ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark, Delaware

MedStar Georgetown University Hospital, Washington, District of Columbia

Washington DC VA Medical Center, Washington, District of Columbia

Baptist Lynn Cancer Institute, Boca Raton, Florida

The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida

Florida Cancer Specialists, Fort Myers, Florida

AdventHealth Orlando, Orlando, Florida

Orlando Health Cancer Institute, Orlando, Florida

Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida

Moffitt Cancer Center, Tampa, Florida

Florida Cancer Specialists & Research Institute, West Palm Beach, Florida

University Cancer And Blood Center LLC, Athens, Georgia

Grady Health System Correll Pavilion, Atlanta, Georgia

Piedmont Healthcare, Atlanta, Georgia

Piedmont Cancer Institute, Atlanta, Georgia

Winship Cancer Institute Emory University, Atlanta, Georgia

City of Hope Cancer Center, Newnan, Georgia

University of Illinois at Chicago, Chicago, Illinois

Cancer Care Specialists of Central Illinois, Decatur, Illinois

Hope and Healing Cancer Services, Hinsdale, Illinois

Illinois Cancer Specialists, Niles, Illinois

City of Hope Chicago, Zion, Illinois

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Investigative Clinical Research of Indiana, LLC, Noblesville, Indiana

Accellacare of McFarland, Ames, Iowa

Maryland Oncology Hematology P A, Silver Spring, Maryland

Boston University Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti, Michigan

University Of Minnesota, Minneapolis, Minnesota

Jackson Oncology Associates, Jackson, Mississippi

Truman Medical Ctr West, Kansas City, Missouri

Washington University School Of Medicine, Saint Louis, Missouri

Oncology Hematology Associates, Springfield, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hunterdon Hematology Oncology, Flemington, New Jersey

Morristown Medical Center, Morristown, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Overlook Medical Center, Summit, New Jersey

Holy Name Medical Center, Teaneck, New Jersey

University of New Mexico, Albuquerque, New Mexico

Montefiore Medical Center, Bronx, New York

Hematology-Oncology Associates of CNY, East Syracuse, New York

Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York

NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York, New York

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York

Ellis Hospital, Schenectady, New York

New York Cancer and Blood Specialists, Shirley, New York

Clinical Research Alliance Inc, Westbury, New York

Regional Medical Oncology Center, Wilson, North Carolina

University of Cincinnati, Cincinnati, Ohio

Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene, Oregon

Oregon Health And Science University, Portland, Oregon

Lankenau Institute for Medical Research Main Line Health Bryn Mawr Hospital, Bryn Mawr, Pennsylvania

Lankenau Institute for Medical Research Main Line Health Paoli Hospital, Paoli, Pennsylvania

Philadelphia VA Medical Center, Philadelphia, Pennsylvania

McGlinn Cancer Institute Reading Hospital, West Reading, Pennsylvania

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

Tennessee Oncology, Chattanooga, Tennessee

Tennessee Cancer Specialists, Knoxville, Tennessee

University of Tennessee, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Tennessee Oncology, Nashville, Tennessee

Texas Oncology DFW, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

Renovatio Clinical, El Paso, Texas

JPS Health Network, Fort Worth, Texas

MD Anderson Cancer Center, Houston, Texas

Oncology Consultants Texas, Houston, Texas

Community Clinical Trials, Kingwood, Texas

Texas Oncology Odessa-West Texas Cancer Center, Odessa, Texas

Renovatio Clinical, The Woodlands, Texas

The University of Texas Health Science Center at Tyler, Tyler, Texas

Texas Oncology-Gulf Coast, Webster, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Vista Oncology, Olympia, Washington

Summit Cancer Centers, Spokane, Washington

Northwest Cancer Specialists - Vancouver, Vancouver, Washington

Auxilio Mutuo Cancer Center, San Juan, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422

Recruiting

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/13/2025

Locations: Banner MD Anderson Cancer Center ( Site 0181), Gilbert, Arizona +155 locations

Banner MD Anderson Cancer Center ( Site 0181), Gilbert, Arizona

Providence St. Jude Medical Center ( Site 0106), Fullerton, California

UCSF Medical Center at Mission Bay ( Site 0178), San Francisco, California

UCHealth Memorial Hospital Central ( Site 0125), Colorado Springs, Colorado

Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207), Greeley, Colorado

Beacon Cancer Care ( Site 0127), Post Falls, Idaho

The University of Chicago Medical Center ( Site 0118), Chicago, Illinois

Massachusetts General Hospital ( Site 0136), Boston, Massachusetts

Dana Farber Cancer Hospital ( Site 0155), Boston, Massachusetts

Ellis Fischel Cancer Center ( Site 0133), Columbia, Missouri

Lake Regional Hospital-Cancer Center ( Site 0123), Osage Beach, Missouri

Montefiore Medical Center ( Site 0160), Bronx, New York

Roswell Park Cancer Institute ( Site 0184), Buffalo, New York

Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse, New York

Icahn School of Medicine at Mount Sinai ( Site 0116), New York, New York

Memorial Sloan Kettering Cancer Center ( Site 0137), New York, New York

SUNY Upstate Cancer Center ( Site 0140), Syracuse, New York

Westchester Medical Center ( Site 0196), Valhalla, New York

University of Cincinnati Medical Center ( Site 0119), Cincinnati, Ohio

St. Lukes Hospital and Health Network ( Site 0186), Bethlehem, Pennsylvania

Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee

MD Anderson Cancer Center ( Site 0150), Houston, Texas

Memorial Hermann Cancer Center ( Site 0172), Houston, Texas

O'Quinn Medical Tower at McNair Campus ( Site 0131), Houston, Texas

The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148), Tyler, Texas

Swedish Cancer Institute ( Site 0143), Seattle, Washington

Virginia Mason Franciscan Health - St. Michael Cancer Center ( Site 0192), Silverdale, Washington

CEMIC ( Site 2454), Caba., Buenos Aires

Fundacion Intecnus ( Site 2456), San Carlos de Bariloche, Rio Negro

Centro Médico IPAM ( Site 2452), Rosario, Santa Fe

Instituto Medico Especializado Alexander Fleming ( Site 2457), Buenos Aires, Not set

Instituto Oncologico de Cordoba -IONC ( Site 2455), Cordoba, Not set

Calvary Mater Newcastle ( Site 2106), Waratah, New South Wales

Tasman Oncology Research ( Site 2104), Southport, Queensland

Princess Alexandra Hospital ( Site 2102), Wooloongabba, Queensland

Grampians Health ( Site 2101), Ballarat, Victoria

One Clinical Research ( Site 2103), Nedlands, Western Australia

Cliniques Universitaires Saint-Luc ( Site 1203), Bruxelles, Bruxelles-Capitale, Region De

Jessa Ziekenhuis ( Site 1204), Hasselt, Limburg

UZ Gent ( Site 1201), Gent, Oost-Vlaanderen

CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 2502), Fortaleza, Ceara

Liga Norte Riograndense Contra o Cancer ( Site 2513), Natal, Rio Grande Do Norte

Hospital Tacchini ( Site 2506), Bento Goncalves, Rio Grande Do Sul

Hospital de Clínicas de Passo Fundo ( Site 2504), Passo Fundo, Rio Grande Do Sul

Hospital Moinhos de Vento ( Site 2510), Porto Alegre, Rio Grande Do Sul

Hospital Nossa Senhora Da Conceicao ( Site 2512), Porto Alegre, Rio Grande Do Sul

Instituto de Oncologia Saint Gallen ( Site 2507), Santa Cruz do Sul, Rio Grande Do Sul

Hospital de Amor - Barretos ( Site 2511), Barretos, Sao Paulo

Instituto Nacional de Câncer - INCA ( Site 2501), Rio de Janeiro, Not set

MBAL Uni Hospital ( Site 1253), Panagyurishte, Pazardzhik

MHAT - Heart and Brain ( Site 1252), Pleven, Not set

Queen Elizabeth II Health Sciences Centre ( Site 1101), Halifax, Nova Scotia

Hamilton Health Sciences - Juravinski Site ( Site 1104), Hamilton, Ontario

Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1105), Kingston, Ontario

Lakeridge Health ( Site 1107), Oshawa, Ontario

McGill University Health Centre ( Site 1103), Montréal, Quebec

IUCPQ ( Site 1112), Québec, Quebec

FALP ( Site 2551), Santiago., Region M. De Santiago

Orlandi Oncologia ( Site 2555), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2556), Santiago, Region M. De Santiago

Bradfordhill ( Site 2552), Santiago, Region M. De Santiago

ONCOCENTRO APYS ( Site 2554), Viña del Mar, Valparaiso

IMAT S.A.S ( Site 2602), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2603), Bogota, Distrito Capital De Bogota

Hospital Universitario San Ignacio ( Site 2610), Bogota, Distrito Capital De Bogota

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 2604), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 2608), Pereira, Risaralda

Fundacion Valle del Lili- CIC ( Site 2601), Cali, Valle Del Cauca

Oulun yliopistollinen sairaala ( Site 1301), Oulu, Pohjois-Pohjanmaa

Turku University Hospital ( Site 1303), Turku, Varsinais-Suomi

CHU Besançon ( Site 1358), Besancon, Franche-Comte

Institut De Cancerologie De L Ouest ( Site 1357), Saint Herblain, Loire-Atlantique

CENTRE LEON BERARD ( Site 1351), Lyon CEDEX 08, Rhone

Marienhaus Klinikum Mainz ( Site 1403), Mainz, Rheinland-Pfalz

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1452), Patras, Achaia

Errikos Dunant Hospital Center ( Site 1457), Athens, Attiki

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1451), Athens, Attiki

Metropolitan Hospital ( Site 1459), Athens, Attiki

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1460), Chaidari, Attiki

University General Hospital of Herakleion ( Site 1458), Herakleion., Irakleio

University General Hospital of Larissa-Oncology Clinic ( Site 1453), Larissa, Thessalia

Papageorgiou General Hospital of Thessaloniki ( Site 1454), Thessaloniki, Not set

Petz Aladár Megyei Oktató Kórház ( Site 1502), Gyor, Gyor-Moson-Sopron

Debreceni Egyetem Altalanos Orvostudomanyi Kar Tudogyogyaszati Tanszek ( Site 1508), Debrecen, Hajdu-Bihar

Mátrai Gyógyintézet ( Site 1504), Mátraháza, Heves

Reformatus Pulmonologiai Centrum-Onkopulmonologiai Jarobeteg Centrum ( Site 1505), Törökbálint, Pest

Somogy Vármegyei Kaposi Mór Oktató Kórház-Oncology center ( Site 1507), Kaposvár, Somogy

Orszagos Koranyi Pulmonologiai Intezet ( Site 1501), Budapest, Not set

Rambam Health Care Campus ( Site 1603), Haifa, Not set

Shaare Zedek Medical Center ( Site 1601), Jerusalem, Not set

Hadassah Medical Center ( Site 1605), Jerusalem, Not set

Sheba Medical Center ( Site 1602), Ramat Gan, Not set

Hospital of the University of Occupational and Environmental Health, Japan ( Site 1166), Kitakyushu, Fukuoka

St. Marianna University Hospital ( Site 1159), Kawasaki, Kanagawa

Kindai University Hospital ( Site 1162), Osakasayama, Osaka

Shizuoka Cancer Center ( Site 1160), Sunto-gun, Shizuoka

National Cancer Center Hospital ( Site 1156), Chuo, Tokyo

Tokyo Medical University Hospital ( Site 1157), Shinjuku, Tokyo

Chiba University Hospital ( Site 1154), Chiba, Not set

National Hospital Organization Kyushu Cancer Center ( Site 1167), Fukuoka, Not set

Fukushima Medical University Hospital ( Site 1151), Fukushima, Not set

Hiroshima University Hospital ( Site 1165), Hiroshima, Not set

Okayama University Hospital ( Site 1164), Okayama, Not set

Wakayama Medical University Hospital ( Site 1163), Wakayama, Not set

National Cancer Center ( Site 2305), Goyang-si, Kyonggi-do

The Catholic University of Korea St. Vincent s Hospital ( Site 2301), Suwonsi, Kyonggi-do

Ajou University Hospital ( Site 2306), Suwon, Kyonggi-do

Seoul National University Hospital ( Site 2303), Seoul, Not set

Severance Hospital Yonsei University Health System ( Site 2302), Seoul, Not set

Samsung Medical Center ( Site 2304), Seoul, Not set

Seoul St. Mary's Hospital ( Site 2307), Seoul, Not set

Medisch Centrum Leeuwarden ( Site 1702), Leeuwarden, Fryslan

Radboudumc ( Site 1706), Nijmegen, Gelderland

Dunedin Hospital ( Site 2202), Dunedin, Otago

Aliada ( Site 2753), Lima, Not set

Detecta Clínica ( Site 2751), Lima, Not set

Krakowski Szpital Specjalistyczny im. Jana Pawla II ( Site 1756), Krakow, Malopolskie

Instytut Gruźlicy i Chorób Płuc w Warszawie ( Site 1764), Warszawa, Mazowieckie

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1759), Przemysl, Podkarpackie

Uniwersyteckie Centrum Kliniczne ( Site 1758), Gdansk, Pomorskie

Swietokrzyskie Centrum Onkologii. ( Site 1754), Kielce, Swietokrzyskie

Warmińsko - Mazurskie Centrum Chorób Płuc w Olsztynie ( Site 1760), Olsztyn, Warminsko-mazurskie

Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1763), Poznan, Wielkopolskie

Centrul Medical Medicover Victoria ( Site 1802), Bucharest, Bucuresti

Institutul Regional de Oncologie ( Site 1804), Iasi, Not set

National Cancer Centre Singapore ( Site 2251), Singapore, Central Singapore

Tan Tock Seng Hospital ( Site 2252), Singapore, Central Singapore

Hospital Clinic de Barcelona ( Site 1919), Barcelona, Cataluna

Complejo Hospitalario Universitario A Coruna ( Site 1916), A Coruña, La Coruna

Hospital Universitario Quiron Madrid ( Site 1913), Pozuelo de Alarcon, Madrid

Hospital Universitari Vall D Hebron ( Site 1910), Barcelona, Not set

Hospital Insular de Gran Canaria ( Site 1911), Canarias, Not set

Hospital General Universitario Gregorio Maranon ( Site 1912), Madrid, Not set

Hospital Quiron Malaga ( Site 1914), Malaga, Not set

Karolinska Universitetssjukhuset Solna ( Site 1951), Stockholm, Stockholms Lan

Chung Shan Medical University Hospital ( Site 2351), Taichung, Not set

China Medical University Hospital ( Site 2358), Taichung, Not set

National Cheng Kung University Hospital ( Site 2354), Tainan, Not set

National Taiwan University Cancer Center (NTUCC) ( Site 2360), Taipei, Not set

Mackay Memorial Hospital ( Site 2355), Taipei, Not set

Taipei Medical University Hospital ( Site 2352), Taipei, Not set

Koo Foundation Sun Yat-Sen Cancer Center ( Site 2359), Taipei, Not set

Taipei Veterans General Hospital ( Site 2357), Taipei, Not set

Chang Gung Memorial Hospital ( Site 2361), Taoyuan, Not set

Hacettepe Universite Hastaneleri ( Site 2001), Sıhhiye, Ankara

Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 2006), Adapazarı, Sakarya

Namık Kemal University Medical Faculty ( Site 2007), Tekirdag, Tekirdas

Ankara Bilkent Sehir Hastanesi ( Site 2002), Ankara, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 2003), Istanbul, Not set

Bristol Haematology and Oncology Centre ( Site 2072), Bristol, Bristol, City Of

St Bartholomews Hospital ( Site 2052), London, London, City Of

Royal Free Hospital ( Site 2074), London, London, City Of

Guys Hospital ( Site 2057), London, London, City Of

Nottingham City Hospital ( Site 2058), Nottingham, Nottinghamshire

St James University Hospital ( Site 2055), Leeds, Not set

The Clatterbridge Cancer Centre ( Site 2069), Wirral, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of SGN-MesoC2 in Advanced Solid Tumors

NCT06466187

Recruiting

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/08/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +23 locations

University of Alabama at Birmingham, Birmingham, Alabama

Mayo Clinic Hospital, Phoenix, Arizona

Mayo Clinic, Scottsdale, Arizona

Mayo Clinic Pharmacy, Jacksonville, Florida

The University of Kansas Clinical Research Center, Fairway, Kansas

The University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas

The University of Kansas Hospital, Kansas City, Kansas

The University of Kansas Medical Center Medical Office Building, Kansas City, Kansas

The University of Kansas Cancer Center - Indian Creek Campus, Overland Park, Kansas

The University of Kansas Cancer Center - Westwood, Westwood, Kansas

Massachusetts General Hospital, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina

James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Ohio State University Hospital, Columbus, Ohio

OSU Brain and Spine Hospital, Columbus, Ohio

Martha Morehouse Tower, Columbus, Ohio

Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Hilliard, Ohio

SCRI Oncology Partners, Nashville, Tennessee

South Texas Accelerated Research Therapeutics, San Antonio, Texas

START Mountain Region, West Valley City, Utah

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario

McGill University Health Centre, Montreal, Quebec

Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial

Learn More ›

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085

Recruiting

Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/05/2025

Locations: MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland +8 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

NCT05456256

Recruiting

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +15 locations

Conditions: Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428

Recruiting

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: University of California at San Diego, La Jolla, California +109 locations

University of California at San Diego, La Jolla, California

University of California Irvine, Orange, California

Stanford Cancer Institute, Stanford, California

Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington, District of Columbia

Baptist Lynn Cancer Institute, Boca Raton, Florida

Mount Sinai Medical Center, Miami Beach, Florida

AdventHealth, Orlando, Florida

H. Lee Moffitt Cancer & Research Institute, Tampa, Florida

University of Kansas Cancer Center, Westwood, Kansas

Sidney Kimmel Cancer Center - Bayview Campus, Baltimore, Maryland

Boston Medical Center, Boston, Massachusetts

Washington University School Of Medicine, Saint Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Hematology-Oncology Associates of CNY, East Syracuse, New York

Novant Health, Charlotte, North Carolina

Novant Health, Winston-Salem, North Carolina

Cleveland Clinic, Cleveland, Ohio

Cleveland Clinic, Mayfield Heights, Ohio

Cleveland Clinic, Warrensville Heights, Ohio

The Huntsman Cancer Institute, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Providence Regional Cancer Partnership, Everett, Washington

Virginia Mason Medical Center, Seattle, Washington

Swedish Cancer Institute, Seattle, Washington

Fundacao Pio XII, Barretos, Not set

PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Not set

Instituto do Cancer de Londrina Hospital do Cancer de Londrina, Londrina, Not set

Associacao Hospitalar Moinhos de Vento, Porto Alegre, Not set

Instituto D Or de Pesquisa e Ensino IDOR, Rio de Janeiro, Not set

Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Not set

Hospital Alemao Oswaldo Cruz, Sao Paulo, Not set

Impar Servicos Hospitalares SA Hospital Nove de Julho, Sao Paulo, Not set

Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Not set

Affiliated Hospital of Hebei University, Bao Ding Shi, Not set

Jilin cancer hospital, Changchun, Not set

Sichuan Cancer Hospital, Chengdu, Not set

West China Hospital Sichuan University, Chengdu, Not set

The First Affiliated Hospital of PLA Army Medical University, ChongQing, Not set

The First Affiliated Hospital Sun Yat sen University, Guangzhou, Not set

The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Not set

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, Not set

Harbin medical university cancer hospital, Harbin, Not set

Huizhou Municipal Central Hospital, Huizhou, Not set

Liuzhou people's Hospital, Liuzhou, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Tianjin Medical University General Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Not set

Hospital of Jiangnan University, Wuxi, Not set

The First Affiliated Hospital of Xian Jiaotong University, XI An, Not set

Yantai Yuhuangding Hospital, Yantai, Not set

Centre Francois Baclesse, Caen Cedex 05, Not set

Centre Georges-François Leclerc, Dijon, Not set

Institut de Cancérologie du Gard, Nîmes, Not set

Institut Curie, PARIS Cedex 5, Not set

Institut de cancerologie de l'ouest, Saint-Herblain Cedex, Not set

Gustave Roussy, Villejuif Cedex, Not set

Evangelische Lungenklinik Berlin, Berlin, Not set

LungenClinic Grosshansdorf GmbH, Grosshandorf, Not set

Lungenfachklinik Immenhausen, Immenhausen, Not set

Universitaetsklinikum Koelnt, Koeln, Not set

Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Wuerzburg, Not set

Rambam Medical Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Meir Medical Center, Kfar Saba, Not set

Rabin Medical Center, Petah Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Policlinico Hospital San Martino- IRCCS for Oncology, Genova, Not set

Ospedale San Raffaele, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Azienda Ospedaliera San Gerardo, Monza, Not set

Azienda Ospedaliera Specialistica dei Colli, Naples, Not set

National Hospital Organization Himeji Medical Center, Himeji, Not set

Matsusaka Municipal Hospital, Matsusaka, Not set

Niigata Cancer Center Hospital, Niigata, Not set

Shizuoka Cancer Center, Shizuoka, Not set

The Cancer Institute Hospital of JFCR, Tokyo, Not set

Wakayama Medical University Hospital, Wakayama, Not set

National Cancer Center, Goyang-Si, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Hospital Tengku Ampuan Afzan, Kuantan, Not set

Hospital Umum Sarawak, Kuching, Not set

Beacon Hospital Sdn Bhd, Petaling Jaya, Not set

Hosp Univ A Coruna, A Coruña, Not set

General University Hospital of Alicantet, Alacant, Not set

Hosp. Del Mar, Barcelona, Not set

Hosp. de La Santa Creu I Sant Pau, Barcelona, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. Univ. La Paz, Madrid, Not set

Hosp Regional Univ de Malaga, Malaga, Not set

Hosp. Virgen Macarena, Sevilla, Not set

Hosp. Clinico Univ. de Valencia, Valencia, Not set

Hosp. Gral. Univ. Valencia, Valencia, Not set

Cheltenham General Hospital, Cheltenham, Not set

Torbay Hospital-Devon, Devon, Not set

Edinburgh Cancer Centre Western General, Edinburgh, Not set

Leicester Royal Infirmary, Leicester, Not set

University College London Hospitals, London, Not set

Nottingham City Hospital, Nottingham, Not set

Queen Alexandra Hospital, Portsmouth, Not set

Conditions: Carcinoma, Non-small-Cell Lung

Learn More ›

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Recruiting

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: University of Connecticut Health Center, Farmington, Connecticut +10 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929

Recruiting

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

07/10/2025

Locations: Massachusetts General Hospital ., Boston, Massachusetts +17 locations

Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms

Learn More ›

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070

Recruiting

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/10/2025

Locations: Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona +38 locations

Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona

City of Hope ( Site 0014), Duarte, California

UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California

Georgetown University ( Site 0036), Washington, District of Columbia

University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky

MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland

Massachusetts General Hospital ( Site 0003), Boston, Massachusetts

Dana Farber Cancer Institute ( Site 0002), Boston, Massachusetts

Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska

Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037), Hackensack, New Jersey

Laura and Isaac Perlmutter Cancer Center ( Site 0034), New York, New York

Sanford Fargo Medical Center ( Site 0039), Fargo, North Dakota

Cleveland Clinic Main ( Site 0006), Cleveland, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus, Ohio

Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania

Sanford Cancer Center ( Site 0038), Sioux Falls, South Dakota

The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas

Petz Aladar Megyei Oktato Korhaz ( Site 0062), Gyor, Gyor-Moson-Sopron

Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061), Szolnok, Jasz-Nagykun-Szolnok

Orszagos Koranyi Pulmonologiai Intezet ( Site 0060), Budapest, Not set

Soroka Medical Center ( Site 0072), Beer-Sheva, Not set

Rambam Health Care Campus-Oncology ( Site 0076), Haifa, Not set

Shaare Zedek Medical Center ( Site 0075), Jerusalem, Not set

Meir Medical Center ( Site 0071), Kfar-Saba, Not set

Rabin Medical Center ( Site 0074), Petah Tikva, Not set

Chaim Sheba Medical Center ( Site 0070), Ramat Gan, Not set

Sourasky Medical Center ( Site 0077), Tel Aviv, Not set

Azienda Ospedaliera Universitaria Careggi ( Site 0173), Florence, Firenze

IRCCS Ospedale San Raffaele ( Site 0171), Milano, Not set

Policlinico Gemelli di Roma ( Site 0174), Roma, Not set

Seoul National University Bundang Hospital ( Site 0081), Seongnam-si, Kyonggi-do

Severance Hospital ( Site 0080), Seoul, Not set

Samsung Medical Center ( Site 0082), Seoul, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151), Warszawa, Mazowieckie

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdansk, Pomorskie

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152), Koszalin, Zachodniopomorskie

ICO L Hospitalet ( Site 0090), Hospitalet de Llobregat, Barcelona

Hospital Universitario Quiron Madrid ( Site 0091), Madrid, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion

NCT06855771

Recruiting

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Alaska Oncology and Hematology, Anchorage, Alaska +70 locations

Alaska Oncology and Hematology, Anchorage, Alaska

Local Institution - 0099, Boise, Idaho

Local Institution - 0090, Boston, Massachusetts

Local Institution - 0100, Detroit, Michigan

Local Institution - 0104, Saint Louis, Missouri

Local Institution - 0018, New York, New York

Local Institution - 0079, Shirley, New York

Local Institution - 0091, Canton, Ohio

Local Institution - 0098, Portland, Oregon

Local Institution - 0103, Portland, Oregon

Local Institution - 0102, Houston, Texas

Local Institution - 0078, Seattle, Washington

Local Institution - 0084, Milwaukee, Wisconsin

GenesisCare - Campbelltown, Campbelltown, New South Wales

Local Institution - 0059, Camperdown, New South Wales

Local Institution - 0058, Woolloongabba, Queensland

Local Institution - 0097, Adelaide, South Australia

Local Institution - 0039, Beijing, Beijing

Local Institution - 0055, Xiamen, Fujian

Local Institution - 0050, Nanning, Guangxi

Local Institution - 0043, Nanchang, Jiangxi

Local Institution - 0056, Changchun, Jilin

Local Institution - 0054, Jinan, Shandong

Local Institution - 0044, Linyi, Shandong

Local Institution - 0049, Hangzhou, Zhejiang

Local Institution - 0053, Linhai, Zhejiang

Local Institution - 0045, Marseille, Bouches-du-Rhône

Local Institution - 0015, La Tronche, Isère

Local Institution - 0012, Saint-Herblain, Loire-Atlantique

Local Institution - 0095, Vandoeuvre lès Nancy, Meurthe-et-Moselle

Local Institution - 0041, Bron, Rhône

Local Institution - 0013, Paris, Not set

Local Institution - 0027, Paris, Not set

Local Institution - 0096, Paris, Île-de-France

Local Institution - 0068, München, Bayern

Local Institution - 0070, Frankfurt, Hessen

Local Institution - 0066, Halle, Sachsen-Anhalt

Local Institution - 0067, Köln, Not set

Local Institution - 0065, Wuerzburg, Not set

Local Institution - 0020, Napoli, Campania

Local Institution - 0026, Napoli, Campania

Local Institution - 0025, Monza, Lombardia

Local Institution - 0022, Milan, Milano

Local Institution - 0024, Bologna, Not set

Local Institution - 0019, Milan, Not set

Local Institution - 0023, Padova, Not set

Local Institution - 0092, Kashiwa, Chiba

Local Institution - 0094, Sendai, Miyagi

Local Institution - 0093, Hirakata, Osaka

Local Institution - 0060, Wieliszew, Mazowieckie

Local Institution - 0064, Prabuty, Pomorskie

Local Institution - 0040, Bucharest, București

Local Institution - 0029, Bucharest, București

Local Institution - 0036, Florești, Cluj

Local Institution - 0031, Craiova, Dolj

Local Institution - 0034, Cluj, Not set

Local Institution - 0030, Iași, Not set

Local Institution - 0032, Iași, Not set

Local Institution - 0074, Barcelona, Barcelona [Barcelona]

Local Institution - 0073, Hospitalet, Barcelona [Barcelona]

Local Institution - 0077, Madrid, Madrid, Comunidad De

Local Institution - 0071, Madrid, Madrid, Comunidad De

Local Institution - 0076, Madrid, Madrid, Comunidad De

Local Institution - 0075, Málaga, Not set

Local Institution - 0089, Sevilla, Not set

Local Institution - 0072, València, Not set

Local Institution - 0002, Solna, Stockholms Län [se-01]

Local Institution - 0003, Gothenburg, Västra Götalands Län [se-14]

Local Institution - 0069, Birmingham, England

Local Institution - 0008, London, London, City Of

Local Institution - 0004, Newcastle upon Tyne, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

13 - 24 of 40